Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › rabeprazole

rabeprazole

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of rabeprazole

24 trials tracked of rabeprazole: 13 in phase 3 or 4 and 1 with published results. The most-cited published study has 30 citations.

24Trials tracked
13Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 3 11 Phase 2 5 Phase 1 5 Other / NA 1
  1. Phase 3 A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients Completed · 30 cited
  2. Phase 4 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed
  3. Phase 4 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed
  4. Phase 3 Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) Completed
  5. Phase 3 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) Completed
  6. Phase 3 Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study) Completed
Show 18 more trials
  1. Phase 3 E3810-A001-313: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers Completed
  2. Phase 3 E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers Completed
  3. Phase 3 A Study of the Safety and Effectiveness of Rabeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients Completed
  4. Phase 3 A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease Completed
  5. Phase 3 Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Completed
  6. Phase 3 Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) Completed
  7. Phase 3 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Completed
  8. Phase 2 Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole Completed
  9. Phase 2 A Study of E3810 for Japanese Subjects With Functional Dyspepsia (SAMURAI Study: Suppression of Acid Milieu With Rabeprazole Improving Functional Dyspepsia ) (Study E3810-J081-204) Completed
  10. Phase 2 A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors Completed
  11. Phase 2 A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules Completed
  12. Phase 2 Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants Completed
  13. Phase 1 A Study of Maribavir Pediatric Formulation in Healthy Adult Participants Completed
  14. Phase 1 A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood Completed
  15. Phase 1 A Study to Evaluate the Effect of a Proton-Pump Inhibitor (Rabeprazole) on the Relative Bioavailability of Cobimetinib in Healthy Participants Completed
  16. Phase 1 Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant Completed
  17. Phase 1 Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers Completed
  18. N/A Study of the Ability of Betaine Hydrochloride to Increase Stomach Acid in Healthy Volunteers Completed

Showing the 24 most-cited and recently-updated of 24 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with increased fracture risk in elderly patients
Drug Pipeline Meta-analysis
Omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with increased fracture risk in elderly patients Some acid reflux medications may increase fracture risk in seniors
This network meta-analysis of 257,445 patients indicates that omeprazole, rabeprazole, pantoprazole, and lansoprazole are associated with in…
New data suggests that certain acid reflux medications may increase the risk of bone fractures for adults over age 65.
Frontiers Sep 13, 2026
Vonoprazan-based regimens show higher H. pylori eradication rates than rabeprazole dual therapy in Chinese cohort
Anesthesiology & Pain Medicine Cohort
Vonoprazan-based regimens show higher H. pylori eradication rates than rabeprazole dual therapy in Chinese cohort A New Stomach Infection Treatment Works Where Old Ones Often Fail
A retrospective cohort study of 598 H. pylori-positive outpatients in Guizhou, China, found vonoprazan-based regimens achieved eradication r…
For millions struggling with a common and stubborn stomach bug, a new treatment approach just proved it can succeed where standard care freq…
Frontiers Apr 11, 2026